On day 26, Leo was in his bedroom, reaching for a glass of water on his nightstand. His left eye, the one he usually kept half-closed because it saw only murky shadows, caught a flicker. He froze. On the periphery of his vision—the dead zone where there had been only black for three years—he saw the curtain move.
One day, Dr. Chen received a letter from him. It contained a single photograph: Leo, grinning, standing next to a telescope. The caption on the back read: "Dr. Chen - I looked at Jupiter tonight. I saw its moons. Not with a camera, but with my own eye. Thank you for teaching the forest to grow." RCTD-418
The “useful” part of the story began with a 12-year-old boy named Leo. On day 26, Leo was in his bedroom,
For five years, she had chased this molecule. RCTD-418 wasn't a typical drug. It wasn't a pill to block a receptor or an antibody to flag a tumor. It was a "retinal cell type director"—a combination of a synthetic signaling protein and a biodegradable scaffold. Its purpose was singular: to convince dormant Müller glial cells in the human eye to stop acting like scar tissue and start acting like photoreceptors. On the periphery of his vision—the dead zone